• 1
    Hinuma Y, Nagata K, Hanaoka M et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 647680.
  • 2
    Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 74159.
  • 3
    Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 1990; 45: 23743.
  • 4
    Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997; 15: 1537.
  • 5
    Osame M, Usuku K, Izumo S et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 10312.
  • 6
    Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 40710.
  • 7
    Mochizuki M, Watanabe T, Yamaguchi K et al. Uveitis associated with human T-cell lymphotropic virus type I. Am J Ophthalmol 1992; 114: 1239.
  • 8
    Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989; 1: 441.
  • 9
    Utsunomiya A, Miyazaki Y, Takatsuka Y et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 1520.
  • 10
    Okamura J, Utsunomiya A, Tanosaki R et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005; 105: 41435.
  • 11
    Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 15918.
  • 12
    Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3: 27682.
  • 13
    Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19: 47596.
  • 14
    Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005; 24: 597685.
  • 15
    Jeang KT, Giam CZ, Majone F, Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004; 279: 319914.
  • 16
    Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 27080.
  • 17
    Kannagi M, Sugamura K, Kinoshita K, Uchino H, Hinuma Y. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient. J Immunol 1984; 133: 103741.
  • 18
    Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990; 348: 2458.
  • 19
    Arnulf B, Thorel M, Poirot Y et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 2004; 18: 12632.
  • 20
    Kato H, Koya Y, Ohashi T et al. Oral administration of human T-cell leukemia virus type 1 induces immune unresponsiveness with persistent infection in adult rats. J Virol 1998; 72: 728993.
  • 21
    Hasegawa A, Ohashi T, Hanabuchi S et al. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J Virol 2003; 77: 295663.
  • 22
    Kannagi M, Harashima N, Kurihara K et al. Tumor immunity against adult T-cell leukemia. Cancer Sci 2005; 96: 24955.
  • 23
    Jacobson S. Human T lymphotropic virus, type-I myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. Curr Opin Neurol 1995; 8: 17983.
  • 24
    Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol 2002; 8: 35964.
  • 25
    Jeffery KJ, Usuku K, Hall SE et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999; 96: 384853.
  • 26
    Bangham CR, Osame M. Cellular immune response to HTLV-1. Oncogene 2005; 24: 603546.
  • 27
    Akimoto M, Kozako T, Sawada T et al. Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers. J Med Virol 2007; 79: 97786.
  • 28
    Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol 2000; 102: 20815.
  • 29
    Kinoshita T, Shimoyama M, Tobinai K et al. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 56204.
  • 30
    Fujisawa J, Seiki M, Kiyokawa T, Yoshida M. Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor. Proc Natl Acad Sci USA 1985; 82: 227781.
  • 31
    Newbound GC, O’Rourke JP, Collins ND, Andrews JM, DeWille J, Lairmore MD. Repression of tax-mediated human t-lymphotropic virus type 1 transcription by inducible cAMP early repressor (ICER) protein in peripheral blood mononuclear cells. J Med Virol 2000; 62: 28692.
  • 32
    Jiang S, Inada T, Tanaka M, Furuta RA, Shingu K, Fujisawa J. Involvement of TORC2, a CREB co-activator, in the in vivo-specific transcriptional control of HTLV-1. Retrovirology 2009; 6: 73.
  • 33
    Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006; 103: 7205.
  • 34
    Kinpara S, Hasegawa A, Utsunomiya A et al. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol 2009; 83: 51018.
  • 35
    Kannagi M, Sugamura K, Sato H, Okochi K, Uchino H, Hinuma Y. Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells. J Immunol 1983; 130: 29426.
  • 36
    Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 1992; 188: 62836.
  • 37
    Kannagi M, Harada S, Maruyama I et al. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV- I-infected cells. Int Immunol 1991; 3: 7617.
  • 38
    Goon PK, Igakura T, Hanon E et al. Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. J Immunol 2004; 172: 173543.
  • 39
    Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med 1993; 177: 156773.
  • 40
    Pique C, Ureta-Vidal A, Gessain A et al. Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides. J Exp Med 2000; 191: 56772.
  • 41
    Macnamara A, Rowan A, Hilburn S et al. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog 2010; 6: e1001117.
  • 42
    Asquith B, Mosley AJ, Barfield A et al. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol 2005; 86: 151523.
  • 43
    Komori K, Hasegawa A, Kurihara K et al. Reduction of human T-cell leukemia virus type 1 (HTLV-1) proviral loads in rats orally infected with HTLV-1 by reimmunization with HTLV-1-infected cells. J Virol 2006; 80: 737581.
  • 44
    Ohashi T, Hanabuchi S, Kato H et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol 2000; 74: 96106.
  • 45
    Hanabuchi S, Ohashi T, Koya Y et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J Natl Cancer Inst 2001; 93: 177583.
  • 46
    Kawano N, Shimoda K, Ishikawa F et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 2006; 82: 8403.
  • 47
    Suzuki S, Uozumi K, Maeda M et al. Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection. Int J Hematol 2006; 83: 42932.
  • 48
    Harashima N, Kurihara K, Utsunomiya A et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 2004; 64: 3919.
  • 49
    Kaplan JE, Osame M, Kubota H et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990; 3: 1096101.
  • 50
    Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 1998; 92: 355761.
  • 51
    Iwanaga M, Watanabe T, Utsunomiya A et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010; 116: 12119.
  • 52
    Nagai M, Usuku K, Matsumoto W et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4: 58693.
  • 53
    Shimizu Y, Takamori A, Utsunomiya A et al. Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Sci 2009; 100: 4819.
  • 54
    Wodarz D, Nowak MA, Bangham CR. The dynamics of HTLV-I and the CTL response. Immunol Today 1999; 20: 2207.
  • 55
    Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR. High frequency of CD4+ FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood 2008; 111: 504753.
  • 56
    Azakami K, Sato T, Araya N et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009; 114: 320815.
  • 57
    Harashima N, Tanosaki R, Shimizu Y et al. Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol 2005; 79: 1008892.
  • 58
    Yamano Y, Nagai M, Brennan M et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 2002; 99: 8894.
  • 59
    Hasui K, Utsunomiya A, Izumo S et al. An immunohistochemical analysis of peripheral blood tissue specimens from leukemia cells: Leukemic cells of Adult T-cell leukemia/lymphoma express p40Tax protein of human T-cell lymphotropic virus type 1 when entering reproliferation. Acta Histochem Cytochem 2003; 36: 34552.
  • 60
    Hinuma Y, Gotoh Y, Sugamura K et al. A retrovirus associated with human adult T-cell leukemia: in vitro activation. Gann 1982; 73: 3414.
  • 61
    Umadome H, Uchiyama T, Hori T et al. Close association between interleukin 2 receptor mRNA expression and human T cell leukemia/lymphoma virus type I viral RNA expression in short-term cultured leukemic cells from adult T cell leukemia patients. J Clin Invest 1988; 81: 5261.
  • 62
    Kurihara K, Harashima N, Hanabuchi S et al. Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer 2005; 114: 25767.
  • 63
    Takeda S, Maeda M, Morikawa S et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 2004; 109: 55967.
  • 64
    Tamiya S, Matsuoka M, Etoh K et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996; 88: 306573.
  • 65
    Koiwa T, Hamano-Usami A, Ishida T et al. 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol 2002; 76: 938997.
  • 66
    Hanon E, Hall S, Taylor GP et al. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000; 95: 138692.
  • 67
    Sodroski J, Rosen C, Goh WC, Haseltine W. A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. Science 1985; 228: 14304.
  • 68
    Nagai K, Jinnai I, Hata T et al. Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells. Int J Hematol 2008; 88: 55164.
  • 69
    Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol 2004; 125: 56875.
  • 70
    Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 2008; 14: 42936.
  • 71
    Colisson R, Barblu L, Gras C et al. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2010; 115: 217785.
  • 72
    Miyatake Y, Ikeda H, Ishizu A et al. Role of neuronal interferon-gamma in the development of myelopathy in rats infected with human T-cell leukemia virus type 1. Am J Pathol 2006; 169: 18999.
  • 73
    Iwakura Y, Tosu M, Yoshida E et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 1991; 253: 10268.
  • 74
    Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9: 49.
  • 75
    Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008; 126: 23542.
  • 76
    Nomura M, Ohashi T, Nishikawa K et al. Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. J Virol 2004; 78: 382736.
  • 77
    Meekings KN, Leipzig J, Bushman FD, Taylor GP, Bangham CR. HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog 2008; 4: e1000027.
  • 78
    Tomaru U, Ikeda H, Ohya O et al. Human T lymphocyte virus type I-induced myeloneuropathy in rats: implication of local activation of the pX and tumor necrosis factor-alpha genes in pathogenesis. J Infect Dis 1996; 174: 31823.
  • 79
    Oliere S, Hernandez E, Lezin A et al. HTLV-1 Evades Type I Interferon Antiviral Signaling by Inducing the Suppressor of Cytokine Signaling 1 (SOCS1). PLoS Pathog 2010; 6: e1001177.